Randomized, Double-blind Study to Evaluate the Tolerability of 2 Different Titration Methods of Rivastigmine Patch in AD Patients (MMSE 10-20)

Inclusion Criteria: * A diagnosis of dementia of the Alzheimer's type according to the DSM-IV criteria * A clinical diagnosis of probable AD according to NINCDS/ADRDA criteria * An MMSE score of ≥ 10 and ≤ 20 at baseline Exclusion Criteria: * Any medical or neurological conditions other than AD that could explain the patient's dementia * A current diagnosis of probable or possible vascular dementia * A score of \> 5 on the Modified Hachinski Ischemic Scale (MHIS) * A current DSM-IV Axis 1 diagnosis that may interfere with the evaluation of the patient's response to study medication. * Treated with donepezil or galantamine within last 4 weeks before the efficacy assessment at baseline. * an advanced severe progressive or unstable disease of any type that may interfere with efficacy and safety assessments or put the patient's at special risk * Other protocol-defined inclusion/exclusion criteria may apply.